CEP
VYGR icon

Chicago Equity Partners’s Voyager Therapeutics VYGR Stock Holding History

Chicago Equity Partners’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-13,630
Closed -$190K – 878
2019
Q4 		$190K Sell
13,630
-9,600
-41% -$140K 0.01% 832
2019
Q3 		$400K Buy
+23,230
New +$488K 0.02% 725

Other funds holding VYGR

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Chicago Equity Partners's VYGR Position: Q1 2020 in Review

Chicago Equity Partners sold out of Voyager Therapeutics (VYGR) in Q1 2020, closing a stake of 13,630 shares — an estimated $190K sold.

Chicago Equity Partners first reported a position in VYGR in Q3 2019 and held it in 2 quarters. The position peaked at $400K in Q3 2019. 121 funds tracked by Wall St. Rank hold VYGR as of Q1 2020.

  • Chicago Equity Partners reported no remaining Voyager Therapeutics position as of Q1 2020 after selling out during the quarter.
  • Chicago Equity Partners sold 13,630 Voyager Therapeutics shares in Q1 2020, an estimated $190K.
  • Chicago Equity Partners first reported a position in Voyager Therapeutics in Q3 2019 and held it in 2 quarters.
  • Chicago Equity Partners's Voyager Therapeutics position peaked at $400K in Q3 2019.
  • 121 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.